We are live on ! Find out more
XBIT icon

XBiotech

56 hedge funds and large institutions have $18.9M invested in XBiotech in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 17 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 17

2.21% less ownership

Funds ownership: 13.25%11.04% (-2.2%)

13% less funds holding

Funds holding: 6456 (-8)

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

46% less capital invested

Capital invested by funds: $34.9M → $18.9M (-$15.9M)

70% less call options, than puts

Call options by funds: $7K | Put options by funds: $23K

Holders
56
Holders Change
-8
Holders Change %
-12.5%
% of All Funds
0.94%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
17
Reduced
17
Closed
21
Calls
$7K
Puts
$23K
Net Calls
-$16K
Net Calls Change
-$27K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$4.81M -$500K -74,384 -8%
Millennium Management
2
Millennium Management
New York
$1.6M +$1.8M +267,953 +1,602%
BlackRock
3
BlackRock
New York
$1.44M -$5.21M -774,178 -75%
CS
4
Credit Suisse
Switzerland
$1.27M +$473K +70,294 +45%
Morgan Stanley
5
Morgan Stanley
New York
$1.13M +$1.11M +165,382 +454%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$941K +$88.7K +13,177 +9%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$852K -$977K -145,274 -49%
OMC
8
Oasis Management Company
Cayman Islands
$772K +$923K +137,174 New
Citadel Advisors
9
Citadel Advisors
Florida
$455K +$267K +39,615 +96%
Renaissance Technologies
10
Renaissance Technologies
New York
$443K +$529K +78,668 New
E
11
Ergoteles
New York
$395K +$472K +70,114 New
Two Sigma Investments
12
Two Sigma Investments
New York
$355K +$346K +51,457 +444%
HF
13
HRT Financial
New York
$338K +$202K +29,981 +99%
State Street
14
State Street
Massachusetts
$325K -$1.79M -266,252 -82%
Bank of New York Mellon
15
Bank of New York Mellon
New York
$314K -$156K -23,181 -29%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$278K +$333K +49,497 New
Connor, Clark & Lunn Investment Management (CC&L)
17
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$277K +$172K +25,509 +108%
Northern Trust
18
Northern Trust
Illinois
$248K -$734K -109,159 -71%
State of Wisconsin Investment Board
19
State of Wisconsin Investment Board
Wisconsin
$241K +$107K +15,972 +60%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$199K +$238K +35,330 New
Two Sigma Advisers
21
Two Sigma Advisers
New York
$179K +$214K +31,800 New
TI
22
Trexquant Investment
Connecticut
$174K +$94.7K +14,069 +83%
TRCT
23
Tower Research Capital (TRC)
New York
$172K +$188K +28,003 +1,067%
BCM
24
Bridgeway Capital Management
Texas
$172K +$205K +30,500 New
CSS
25
Cubist Systematic Strategies
Connecticut
$153K +$183K +27,251 New

XBIT Hedge Fund Activity: Q2 2022 in Review

56 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2022, worth a combined $18.9M — down 46% from $34.9M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of XBIT and 14 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 17 added.

The largest buyer was Millennium Management, adding an estimated $1.8M. The largest seller was BlackRock, cutting an estimated $5.21M.

  • 56 institutional investors held XBiotech (XBIT) as of Q2 2022, down from 64 in Q1 2022.
  • Funds reported $18.9M of XBiotech stock for Q2 2022, down 46% quarter-over-quarter.
  • 14 funds opened new XBiotech positions in Q2 2022 and 21 closed out, a net change of -7 holders.
  • The largest XBiotech buyer in Q2 2022 was Millennium Management, an estimated $1.8M added.
  • The largest XBiotech seller in Q2 2022 was BlackRock, an estimated $5.21M sold.

Based on aggregated 13F filings for Q2 2022.